Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 3, 2001, Pages 145-157

  Saul, J Philip ^a,b,c,d,e   Ross, Bertrand ^a,b,c,d,e   Schaffer, Michael S ^a,b,c,d,e   Beerman, Lee ^a,b,c,d,e   Melikian, Armen P ^a,b,c,d,e   Shi, Jun ^a,b,c,d,e   Williams, John ^a,b,c,d,e   Barbey, Jean T ^a,b,c,d,e   Jin, Judy ^a,b,c,d,e   Hinderling, Peter H ^a,b,c,d,e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Children's Hospital of the King's Daughters   (United States)

^c Children's Hospital   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERABILITY; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; INFANT; LIQUID CHROMATOGRAPHY; MALE; NEWBORN; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL; SUPRAVENTRICULAR TACHYCARDIA; TANDEM MASS SPECTROMETRY;

ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METABOLIC CLEARANCE RATE; SOTALOL; TACHYCARDIA, SUPRAVENTRICULAR; TACHYCARDIA, VENTRICULAR;

EID: 0035103549     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.113795     Document Type: Article

References (34)

1. The current labeling for Betapace® (sotalol HCl)
2. Effectiveness of oral sotalol treatment of pediatric arrhythmia
3. Efficacy and proarrhythmia of oral sotalol in pediatric patients
4. Sotalol for refractory arrhythmias in pediatric and young adult patients: Initial efficacy and long-term outcome
5. Effectiveness of sotalol for atrial flutter in children after surgery for congenital heart disease
6. The current labeling for Betapace AF™ (sotalol HCl)
7. Human pharmacokinetics of sotalol
8. Clinical pharmacokinetics of sotalol
9. Single dose phannacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia
10. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children and adolescents
11. Simplified calculation of body-surface area
12. An analysis of the time-relations of electrocardiograms
13. Die Systolendauer im Elektrocardiogramm bei normalen Menschen und bei Herzkranken
14. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia
15. Clinical pharmacokinetics in newborns and infants: Age related differences and therapeutic implications
16. Clinical pharmacokinetics in infants and children: A reappraisal
17. Clinical pharmacokinetics in heart failure, an updated review
18. Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure
19. Intravenous quinidine in congestive cardiomyopathy
20. Oxaprozin pharmacokinetics in patients with congestive heart failure
21. Effect of congestive heart failure on the pharmacokinetics of cibenzoline
22. Ibopamin kinetics after single oral dose in patients with congestive heart failure
23. The effect of age and cardiac failure on xamoterol pharmacokinetics
24. Disposition of procainamide in patients with chronic congestive heart failure receiving medical therapy
25. The QT interval in atrial fibrillation
26. Digoxin
27. Antiarrhythmic drugs
28. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs
29. Observations on the efficacy and pharmacokinetics of sotalol after oral administration
30. Concentration dependent pharmacologic properties of sotalol
31. Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers
32. Pharmacokinetics and pharmacodynamics of (±) sotalol in healthy male volunteers
33. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects